Correction: Safety of immune checkpoint inhibitors for cancer treatment: real-world retrospective data analysis from Qatar (SAFE-ICI-Q study) - Top-Institutions - MDSpire

Correction: Safety of immune checkpoint inhibitors for cancer treatment: real-world retrospective data analysis from Qatar (SAFE-ICI-Q study)

  • By

  • Nabil E. Omar

  • Shereen Elazzazy

  • Anas Hamad

  • Mohamed Omar Saad

  • Aya Alasmar

  • Sahar M. Nasser

  • Maria Benkhadra

  • Hebatalla M. Afifi

  • Farah I. Jibril

  • Rawan A. Dawoud

  • Mohamed S. Hamid

  • Afnan Alnajjar

  • Arwa O. Sahal

  • Amaal Gulied

  • Hazem Elewa

  • June 19, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology
    • Immunotherapy

  • #2

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, Massachusetts

    Key Differentiators

    • Oncology
    • Hematology

  • #3

    Massachusetts General Hospital
    Massachusetts General Hospital

    Boston, Massachusetts

    Key Differentiators

    • Oncology
    • Cardiology

  • #4

    Roswell Park Comprehensive Cancer Center
    Roswell Park Comprehensive Cancer Center

    Buffalo, New York

    Key Differentiators

    • Oncology
    • Hematology

Original Source(s)

Correction: Safety of immune checkpoint inhibitors for cancer treatment: real-world retrospective data analysis from Qatar (SAFE-ICI-Q study)

  • by Nabil E. Omar, Shereen Elazzazy, Anas Hamad, Mohamed Omar Saad, Aya Alasmar, Sahar M. Nasser, Maria Benkhadra, Hebatalla M. Afifi, Farah I. Jibril, Rawan A. Dawoud, Mohamed S. Hamid, Afnan Alnajjar, Arwa O. Sahal, Amaal Gulied, Hazem Elewa

  • June 19, 2026

Related Content

Temporal dynamics and determinants of early recurrence after curative resection for stage I-III rectal cancer: integrated analyses of hazard function, survival, and competing risks

From ribosomopathies to therapeutic targets: ribosomal alterations in pediatric leukemogenesis and tumorigenesis

Effects of surgery on cancer metastasis: biological mechanisms and perioperative implications